Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Saved in:
| Title: | Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. |
|---|---|
| Authors: | Motzer, R.J.1 (AUTHOR) motzerr@mskcc.org, Escudier, B.2 (AUTHOR), Burotto, M.3 (AUTHOR), Powles, T.4 (AUTHOR), Apolo, A.B.5 (AUTHOR), Bourlon, M.T.6 (AUTHOR), Shah, A.Y.7 (AUTHOR), Porta, C.8 (AUTHOR), Suárez, C.9 (AUTHOR), Barrios, C.H.10 (AUTHOR), Richardet, M.11 (AUTHOR), Gurney, H.12 (AUTHOR), Kessler, E.R.13 (AUTHOR), Tomita, Y.14,15 (AUTHOR), Bedke, J.16 (AUTHOR), Scheffold, C.17 (AUTHOR), Askelson, M.18 (AUTHOR), Panzica, J.19 (AUTHOR), Zhang, J.20 (AUTHOR), van Kooten Losio, M.1,21 (AUTHOR) |
| Source: | Annals of Oncology. Jan2026, Vol. 37 Issue 1, p33-43. 11p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
